

Product Datasheet

Vevorisertib trihydrochloride

Catalog No. **BP-02268A** · CAS **1416775-08-0** · Form **salt · hydrochloride** · Physical state **solid** · Color **White to off-white** · Version **1.0** · Revision **2026-09-04**


FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.

Target Akt	Research area Cancer
----------------------	--------------------------------

Molecular formula **C₃₅H₄₁Cl₃N₈O**

Molecular weight **696.1120**

STRUCTURE



DESCRIPTION

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has K_d values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively.

BIOLOGICAL ACTIVITY

Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has K_d values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer.

SOLUBILITY

Soluble in DMSO/H₂O

In vitro DMSO : 100 mg/mL H₂O : 25 mg/mL

REFERENCES

- [1]. Yu Y, et al. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLoS One. 2015 Oct 15;10(10):e0140479.
- [2]. Kozinova M, et al. Combined Inhibition of AKT and KIT Restores Expression of Programmed Cell Death 4 (PDCD4) in Gastrointestinal Stromal Tumor. Cancers (Basel). 2021 Jul 23;13(15):3699.

Tel: +86 20 31130026 · Fax: +86 20 36822386 · tech@biochemprobe.com · www.biochemprobe.com

BiochemProbe is the catalog brand of Guangzhou Yuyuan Biotech Co., Ltd. · For research use only.

Lot CoA and SDS are separate documents.